Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 6, 2012, Pages 563-569

  Yokoe, Hiroshi ^a   Yuasa, Fumio ^a   Yuyama, Reisuke ^a   Murakawa, Kousuke ^a   Miyasaka, Yoko ^a   Yoshida, Susumu ^a   Tsujimoto, Satoshi ^a   Sugiura, Tetsuro ^b   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

arterial baroreflex sensitivity; insulin resistance; myocardial infarction; sympathetic nerve activity

Indexed keywords

ADIPONECTIN; PIOGLITAZONE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPATHETIC BLOCKING; SYMPATHETIC FUNCTION;

ADIPONECTIN; AGED; BAROREFLEX; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SYMPATHETIC NERVOUS SYSTEM; THIAZOLIDINEDIONES;

EID: 84862194175     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31824f91a7     Document Type: Article

References (33)

1. Mark KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:171-179.
2. Abbud ZA, Shindler DM, Wilson AC, et al. Effect of diabetes mellitus on short and long-Term mortality rates of patients with acute myocardial infarction: A statewide study. Myocardial Infarction Data Acquisition System Study Group. Am Heart J. 1995;130:51-58.
3. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J. 1988;9:259-264.
4. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119-124.
5. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772-1780.
6. La Rovere MT, Specchia G, Mortara A, et al. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation. 1988; 78:816-824.
7. La Rovere MT, Bigger JT Jr, Marcus FL, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998;351:478-484.
8. Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and electrophysiological correlates in patients after acute myocardial infarction. Circulation. 1991;83:945-952.
9. De Ferrari GM, Lindolina M, Mantica M, et al. Baroreflex sensitivity, but not heart rate variability, is reduced in patients with life-Threatening ventricular arrhythmias long after myocardial infarction. Am Heart J. 1995;130:173-180.
10. De Ferrari GM, Sanzo A, Bertoletti A, et al. Baroreflex sensitivity predicts long-Term cardiovascular mortality after myocardial infarction even in patients with preserved left ventricular function. J Am Coll Cardiol. 2007;50:2285-2290.
11. Straznicky NE, Lambert GW, Lambert EA. Neuroadrenergic dysfunction in obesity: An overview of the effects of weight loss. Curr Opin Lipidol. 2010;21:21-30.
12. Young CN, Deo SH, Chaudhary K, et al. Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. J Physiol. 2010;588:3593-3603.
13. Nagai Y, Sugiyama Y, Nakatsumi Y, et al. Rapid amelioration of muscle sympathetic nerve activity by pioglitazone in an obese type 2 diabetic patient. Diabet Med. 2003;20:867-869.
14. Kobayashi D, Takamura M, Murai H, et al. Effect of pioglitazone on muscle sympathetic nerve activity in type 2 diabetes mellitus with alphaglucosidase inhibitor. Auton Neurosci. 2010;158:86-91.
15. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arterial pressure during sleep in man. A quantitative method of assessing baroreflex sensitivity. Circ Res. 1969;24:109-121.
16. Mimura J, Yuasa F, Yuyama R, et al. The effect of residential exercise training on baroreflex control of heart rate and sympathetic nerve activity in patients with acute myocardial infarction. Chest. 2005;127:1108-1115.
17. Mark AL, Victor RG, Nerhed C, et al. Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans. Circ Res. 1985;57:461-469.
18. Grassi G, Seravalle G, Calhoun DA, et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994;50:248-253.
19. Katsui A, Araki-Sasaki R, Sumida Y, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362-365.
20. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75: 809-817.
21. Lucas CP, Estigarribia JA, Darga LL, et al. Insulin and blood pressure in obesity. Hypertension. 1985;7:702-706.
22. Muntzel MS, Anderson EA, Johnson AK, et al. Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens. 1995;17:39-50.
23. Pricher MP, Freeman KL, Brooks VL. Insulin in the brain increases gain of baroreflex control of heart rate and lumbar sympathetic nerve activity. Hypertension. 2008;51:514-520.
24. Ruggeri P, Molinari C, Brunori A, et al. The direct effect of insulin on barosensitive neurones in the nucleus tractus solitarii of rats. Neuroreport. 2001;12:3719-3722.
25. Van Houten M, Posner BI. Circumventricular organs: Receptors and mediators of direct peptide hormone action on brain. Adv Metab Disord. 1983;10:269-289.
26. Sauter A, Goldstein M, Engel J, et al. Effect of insulin on central catecholamines. Brain Res. 1983;260:330-333.
27. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care. 2008;31: 121-127.
28. Kasai T, Miyauchi K, Yokoyama T, et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis. 2008;197:612-619.
29. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
30. Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferatoractivated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102: 1834-1839.
31. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-Activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
32. Kavanagh K, Brown KK, Berquist ML, et al. Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: Implications for peroxisome proliferator-Activated receptor-gamma agonist use in prediabetes. Metabolism. 2010;59:914-920.
33. Madden KM, Lockhart C, Potter TF, et al. Aerobic training restores arterial baroreflex sensitivity in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. Clin J Sport Med. 2010;20: 312-317.